Free Trial

Genscript Biotech (GNNSF) News Today

Genscript Biotech logo
C$1.36 0.00 (0.00%)
As of 01/29/2025
3 Stocks That May Be Undervalued In December 2024
Genscript Biotech Aligns Interests with Restricted Share Grant
Genscript Biotech Strikes Lucrative Licensing Deal
Genscript Reports on Legend Biotech’s Q3 Financials
Genscript Biotech’s CARVYKTI Shows Promise in Myeloma Treatment
Genscript Biotech Announces Deconsolidation of Legend Biotech
Genscript Biotech Corporation (GNNSF)
GenScript Biotech Reports First Half 2024 Results
GNNSF Genscript Biotech Corporation
Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
Genscript Biotech Corporation - Class H (GNNSF)
GenScript Named a BioSpace 2024 Best Place to Work
Get Genscript Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNNSF and its competitors with MarketBeat's FREE daily newsletter.

GNNSF Media Mentions By Week

GNNSF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GNNSF
News Sentiment

0.00

0.74

Average
Medical
News Sentiment

GNNSF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GNNSF Articles
This Week

1

0

GNNSF Articles
Average Week

Get Genscript Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNNSF and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (OTCMKTS:GNNSF) was last updated on 1/30/2025 by MarketBeat.com Staff
From Our Partners